New treatments for IDH‑mutant brain tumors
Project 3: Targeting IDH mutant gliomas
Developing new treatment approaches for people with IDH‑mutant brain tumors, including those that come back after current IDH‑targeted drugs.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11178594 on NIH RePORTER |
What this research studies
Many lower‑grade and some higher‑grade brain tumors carry mutations in IDH enzymes that create a cancer‑promoting molecule called (R)‑2HG. This project studies how (R)‑2HG changes tumor cells and why some tumors stop responding to IDH inhibitor drugs like vorasidenib. The team will use patient tumor samples, laboratory models, and molecular testing to find specific weaknesses in tumors that recur after IDH inhibitor therapy. Promising targets will be developed with the aim of moving new, more effective treatments toward clinical testing.
Who could benefit from this research
Good fit: Adults with IDH‑mutant lower‑grade or recurrent gliomas, particularly those who have progressed after IDH‑inhibitor treatments, are the most relevant candidates.
Not a fit: Patients whose tumors do not carry IDH mutations or who cannot access participating centers are unlikely to benefit directly from this work.
Why it matters
Potential benefit: Could provide new targeted treatment options for patients with IDH‑mutant gliomas, especially those whose tumors recur after IDH inhibitor therapy.
How similar studies have performed: IDH inhibitors such as vorasidenib have already improved outcomes in IDH‑mutant gliomas, but strategies specifically targeting tumors that recur after these drugs are largely untested.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Mcbrayer, Samuel Kent — Brigham and Women's Hospital
- Study coordinator: Mcbrayer, Samuel Kent
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.